Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above ...

Free body diagrams do not need to be drawn to scale but it can sometimes be useful if they are. It is important to label each arrow to show the magnitude of the force it represents. The type of ...